Incara Pharmaceuticals Inactive 10-Q2003 Q1 Quarterly report

Filed: 13 Feb 03, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: applied, assigned, book, bowl, Certification, commonly, compensation, concluded, conserve, contractual, corrective, covered, data, defer, design, designed, disclosed, disposal, ensure, entity, equivalent, exit, fact, FASB, field, FIN, fraud, free, function, guarantee, guarantor, guidance, impact, inactive, income, Indirect, individual, intellectual, interpretation, invoiced, involuntarily, joint, justify, light, measurement, merge, misleading, modified, nature, noncash, November, pay, policy, primary, prior, prominent, property, prospective, reactive, receipt, referred, relocate, rent, rental, Rescission, responsibility, responsible, restructuring, role, safe, salary, scope, secondary, senior, showed, shown, Sr, strategic, study, sublease, supervision, temporarily, terminated, terminating, termination, uncertainty, untrue, venture, Vesta, voluntarily, wrote

Removed: adverse, affected, amortization, amortized, annualized, applicable, application, August, back, billable, borrow, borrowed, borrowing, charged, classified, collateral, conducted, conducting, consent, continued, cost, criteria, damage, damaged, decrease, deemed, delay, delisted, dependence, discontinuation, disputed, earned, establishment, excluding, existing, extraordinary, fail, failure, finance, finite, flow, focused, forty, goodwill, heparin, impairment, indefinite, injury, intangible, interest, Irish, Item, July, life, limited, liquidation, listing, lived, longer, March, meeting, minimum, molecular, molecule, mutual, Nasdaq, National, negative, past, performed, personnel, pledged, Presentation, President, previously, price, principal, processing, progenitor, protection, regeneration, repair, required, scale, separately, settlement, specific, sponsored, stroke, tested, therapy, tissue, Transamerica, transfer, unallocated, Vice, weight, work, written

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Incara Pharmaceuticals similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 99.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Incara Pharmaceuticals Corporation (the “Company”) for the period ended December 31, 2002 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Clayton I. Duncan, President and Chief Executive Officer, hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ CLAYTON I. DUNCAN

Clayton I. Duncan

President and Chief Executive Officer

February 13, 2003